Growth Metrics

Ptc Therapeutics (PTCT) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to $2.6 billion.

  • Ptc Therapeutics' Liabilities and Shareholders Equity rose 4350.5% to $2.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.6 billion, marking a year-over-year increase of 2947.84%. This contributed to the annual value of $1.7 billion for FY2024, which is 1005.82% down from last year.
  • According to the latest figures from Q3 2025, Ptc Therapeutics' Liabilities and Shareholders Equity is $2.6 billion, which was up 4350.5% from $2.6 billion recorded in Q2 2025.
  • Over the past 5 years, Ptc Therapeutics' Liabilities and Shareholders Equity peaked at $2.7 billion during Q1 2025, and registered a low of $1.3 billion during Q3 2023.
  • Its 5-year average for Liabilities and Shareholders Equity is $1.9 billion, with a median of $1.8 billion in 2024.
  • Per our database at Business Quant, Ptc Therapeutics' Liabilities and Shareholders Equity plummeted by 2582.7% in 2023 and then skyrocketed by 4837.64% in 2025.
  • Quarter analysis of 5 years shows Ptc Therapeutics' Liabilities and Shareholders Equity stood at $1.9 billion in 2021, then fell by 11.99% to $1.7 billion in 2022, then rose by 11.14% to $1.9 billion in 2023, then dropped by 10.06% to $1.7 billion in 2024, then surged by 55.05% to $2.6 billion in 2025.
  • Its Liabilities and Shareholders Equity was $2.6 billion in Q3 2025, compared to $2.6 billion in Q2 2025 and $2.7 billion in Q1 2025.